Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Maintenance in DLBCL
NCT03311958Phase 1Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- May 2018
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Fox Chase Cancer Center. Primary endpoints: Rate of conversion from positive to negative ctDNA at 2 years and Relapse Free Survival (RFS-ctDNA) at 2 years. Started May 2018; status: completed.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03311958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311958.